MA01.07 Long-Term Analysis of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy (ccrt) -/+ Metformin in Locally Advanced NSCLC
Recommended Citation
Tsakiridis T, Hu C, Skinner H, Santana-Davila R, Lu B, Erasmus JJ, Doemer AJ, Videtic GM, Wang F, Hesselle M, Lee RY, Werner-Wasik M, Schaner PE, McCormack SE, Esparaz BT, McGarry RC, Brownstein J, Struve T, Lyness JA, Bradley JD. MA01.07 Long-Term Analysis of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy (ccrt) -/+ Metformin in Locally Advanced NSCLC. J Thorac Oncol 2024; 19(10):S53-S54.
Document Type
Conference Proceeding
Publication Date
10-1-2024
Publication Title
J Thorac Oncol
Abstract
The highly active glycolytic metabolism of non-small cell lung cancer (NSCLC) is an attractive target for metabolic therapies. NRG-LU001 (NCT02186847) was a phase II trial that found that the addition of anti-diabetic agent metformin, a mitochondrial inhibitor, to the standard of care cCRT did not improve 1-year progression-free survival (PFS) in locally advanced (LA)-NSCLC. Here, we present the long-term analysis with 5-year follow-up.
Volume
19
Issue
10
First Page
S53
Last Page
S54
